Mindstate Design Labs

Mindstate Design Labs is a clinical-stage AI neuroengineering platform and drug development company addressing the mental health crisis. The Osmanthus platform maps the biological basis of emotion, perception, and cognition by synthesizing 60,000 human reports with biochemical data. It uses multi-agent LLMs, Bayesian neural networks, and embedding models to identify specific neurotransmitter receptor combinations that produce distinct emotional states. The lead asset, MSD-001, is in human studies to induce targeted states like empathy and awe. Targeting biotech researchers and developers, the platform aims to create precision-designed therapeutics. Pricing information is not publicly available.